o a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10659800		
Filing Date		2003-09-10		
First Named Inventor Fares Art Unit		se		
		1652		
Examiner Name	Hutso	on, Richard		
Attorney Docket Number		UCAL-105CIP2CON2		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6607893		2003-08-19	Warner-Lambert Company	
	2	6552250		2003-04-22	Nykiforuk et al.	
	3	7015373		2006-03-21	Zou et al.	
	4	6100077		1998-10-01	Sturley et al.	
If you wish	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20060090222		2006-27-04	Zou et al.	
	2	20050193446		2005-09-01	Zou et al.	
If you wish	h to ac	t dd additional U.S. Publis	hed Ap	plication citatio	n information please click the Ad-	d button Add

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) First Named I Art Unit Examiner Nar

Application Number		10659800		
Filing Date		2003-09-10		
First Named Inventor	Farese			
Art Unit		1652		
Examiner Name	Hutso	on, Richard		
Attorney Docket Number		UCAL-105CIP2CON2		

Examiner Initial*	Cite No	Foreigr Numbe	Document	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Appl	ne of Patentee or licant of cited ument	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1									
If you wish	h to a	dd additi	onal Foreign F	atent Document	citation	information pl	lease	click the Add butto	n Add	
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Cite No						Тŝ			
	1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Knd. Octobe of USPTO Plantin Documents at year, <u>USPTO, DOCY</u> or MPEP 901.04. \* Enter office and issued for document, by the to-eleter code (WIPO Standard ST3.). \*\*Explainese plantin documents, the advalation of the paut of the region of the Engerer many legacine due senal number of the plantin document. \*\*India of document by the appropriate symbol as andicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here it from the plantin structure at marketines in attached.\*\*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10659800	
Filing Date		2003-09-10	
First Named Inventor	Farese		
Art Unit		1652	
Examiner Name	Hutso	on, Richard	
Attorney Docket Number		UCAL-105CIP2CON2	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a deepin patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paula A. Borden/	Date (YYYY-MM-DD)	2006-05-17
Name/Drint	Dovin A Domina	Registration Number	42344

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field end by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademán Yoffice, U.S. Organized not Comment of Comments of C

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.